What's Happening?
CytoSorbents Corporation, a leader in blood purification technologies, announced its participation in the Jefferies Global Healthcare Conference in London. The company will present and engage in one-on-one
meetings with investors from November 17-20, 2025. CytoSorbents specializes in treating life-threatening conditions in intensive care units and cardiac surgery through its proprietary blood purification technologies. These technologies utilize biocompatible polymer beads to remove toxic substances from blood and bodily fluids. The company's lead product, CytoSorb, is approved in the European Union and distributed in over 70 countries, with nearly 300,000 devices used to date. CytoSorbents is also developing the DrugSorb-ATR system for antithrombotic removal, which has received FDA Breakthrough Device Designations for specific applications but is not yet approved in the U.S. or Canada.
Why It's Important?
CytoSorbents' participation in the Jefferies Global Healthcare Conference highlights its ongoing efforts to expand its market presence and secure regulatory approvals for its innovative blood purification technologies. The company's products address critical medical needs, such as reducing severe bleeding during surgery and managing inflammation in critical illnesses. With FDA Emergency Use Authorization for CytoSorb in COVID-19 patients, the company is positioned to play a significant role in the U.S. healthcare market. Successful regulatory approval of DrugSorb-ATR could further enhance its impact, offering new solutions for managing perioperative bleeding risks associated with blood thinners.
